Cargando…
Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC
Lung cancer remains a leading cause of death globally, with the most frequent type, nonsmall cell lung cancer (NSCLC), having a 5-year survival rate of less than 20%. While platinum-based doublet chemotherapy is currently first-line therapy for advanced disease, it is associated with only modest cli...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116793/ https://www.ncbi.nlm.nih.gov/pubmed/21691577 http://dx.doi.org/10.2147/OTT.S18155 |